Kura Oncology, Inc. is a US-based pharmaceutical company specializing in developing therapies for solid tumors and blood cancers. They focus on small-molecule product candidates targeting cell signaling pathways to treat various forms of cancer. With an ESG risk rating score of 24.6, the company is classified as having a medium risk level. Kura Oncology's main product candidate, Tipifarnib, is a farnesyl transferase inhibitor used in the treatment of both solid tumors and blood cancers. Operations are primarily focused within the United States.